


Stabilis



Ketorolac tromethamine



Noms commerciaux

Bedoral	Afrique du sud
Ketorolac trometamol	Grande Bretagne
Lixidol	Italie
Taradyl	Belgique
Toradol	Danemark, Espagne, Finlande, Grande Bretagne, Italie, Norvège, Suède



Stabilité des solutions

		0,6 mg/ml	25°C		48			469
PVC		0,3 & 0,6 mg/ml	23°C		21			1634
PVC		0,6 mg/ml	25°C		48			469
PVC		0,6 mg/ml	25°C		35			451
PVC		0,6 mg/ml	5°C		50			451
PVC		0,6 mg/ml	25°C		7			451
PVC		0,6 mg/ml	5°C		50			451
PVC	RL	0,6 mg/ml	25°C		48			469
PE		0,1 & 0,3 mg/ml	-20°C		15			2124
PE		0,1 & 0,3 mg/ml	4°C		35			2124
PE		0,2 mg/ml	-20°C		90			2015
PE		0,2 mg/ml	4°C		60			2015



Stabilité en mélange

		10 mg/ml	25°C		Thiocolchicoside : 1 mg/ml	3		1859

PVC		2 mg/ml	25°C		Tramadol hydrochloride : 20 mg/ml	7		3159
PP		10 mg/ml	25°C		Tramadol hydrochloride : 33,3 mg/ml	7		3159
PP		30 mg/ml	25°C		Paracetamol : 10 mg/ml	4		3571
PP		1,5 mg/ml	4°C		Famotidine : 0,4 mg/ml Metoclopramide hydrochloride : 0,5 mg/ml Hydromorphone hydrochloride : 10 mg/ml	96		2166



Compatibilités

		Ketorolac tromethamine : 15 mg/ml Azithromycine : 2 mg/ml	1800
		Ketorolac tromethamine : 15 mg/ml Cisatracurium besylate : 0.1 >> 5 mg/ml	299
		Ketorolac tromethamine Cisatracurium besylate	3601
		Ketorolac tromethamine : 30 mg/ml Cyclizine lactate : 50 mg/ml	3374
		Ketorolac tromethamine : 15 mg/ml Dexmedetomidine : 4 µg/ml	1712
		Ketorolac tromethamine : 30 mg/ml Diazepam : 5 mg/ml	476
		Ketorolac tromethamine : 15 mg/ml Fenoldopam mesylate : 80 µg/ml	1803
		Ketorolac tromethamine : 1 mg/ml Fentanyl citrate : 25 µg/ml	1974
		Ketorolac tromethamine : 30 mg/ml Haloperidol lactate : 5 mg/ml	228
		Ketorolac tromethamine : 15 mg/ml Hetastarch : 60 mg/ml	1721
		Ketorolac tromethamine : 15 mg/ml Hydromorphone hydrochloride : 10 mg/ml	216
		Ketorolac tromethamine : 30 mg/ml Hydromorphone hydrochloride : 1 mg/ml	216
		Ketorolac tromethamine : 15 mg/ml Hydromorphone hydrochloride : 1 mg/ml	216
		Ketorolac tromethamine : 30 mg/ml Hydromorphone hydrochloride : 10 mg/ml	216
		Ketorolac tromethamine : 1 mg/ml Hydromorphone hydrochloride : 0.5 mg/ml	1974
		Ketorolac tromethamine Hydroxyzine dihydrochloride	3593
		Ketorolac tromethamine : 15 mg/ml Hydroxyzine dihydrochloride : 12.5 mg/ml	228
		Ketorolac tromethamine : 30 mg/ml Hydroxyzine dihydrochloride : 50 mg/ml	476
		Ketorolac tromethamine : 30 mg/ml Imipenem-Cilastatin / Relebactam : 5 mg/ml	4433

	Ketorolac tromethamine : 1.76 >> 5.29 mg/ml Methadone hydrochloride : 0.59 >> 2.94 mg/ml		3470
	Ketorolac tromethamine : 1 mg/ml Methadone hydrochloride : 1 mg/ml		1974
	Ketorolac tromethamine : 3,4 >> 4 mg/ml Morphine hydrochloride : 1,3 >> 3 mg/ml		3169
	Ketorolac tromethamine : 1.76 mg/ml Morphine hydrochloride : 4.7 mg/ml		3470
	Ketorolac tromethamine : 1.76 & 3.53 mg/ml Morphine hydrochloride : 1.18 >> 3.53 mg/ml		3470
	Ketorolac tromethamine : 1 mg/ml Morphine sulfate : 1 mg/ml		1974
	Ketorolac tromethamine Morphine sulfate		3593
	Ketorolac tromethamine : 30 mg/ml Nalbuphine hydrochloride : 10 mg/ml		476
	Ketorolac tromethamine : 30 mg/ml Paracetamol : 10 mg/ml		4435
	Ketorolac tromethamine : 30 mg/ml Paracetamol : 10 mg/ml		3571
	Ketorolac tromethamine Pethidine hydrochloride		3593
	Ketorolac tromethamine : 30 mg/ml Prochlorperazine edysilate : 5 mg/ml		476
	Ketorolac tromethamine Promethazine hydrochloride		3593
	Ketorolac tromethamine : 30 mg/ml Promethazine hydrochloride : 25 mg/ml		476
	Ketorolac tromethamine : 15 mg/ml Remifentanil hydrochloride : 25 & 250 µg/ml		59
	Ketorolac tromethamine : 10 mg/ml Thiocolchicoside : 1.33 mg/ml		1859
	Ketorolac tromethamine : 10 mg/ml Tramadol hydrochloride : 33.3 mg/ml		3159
	Ketorolac tromethamine : 2 mg/ml Tramadol hydrochloride : 20 mg/ml		3159



Voie d'administration



Bibliographie

Type	Source
59 Revue	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.

216	Revue	Huang E, Anderson RP. Compatibility of hydromorphone hydrochloride with haloperidol lactate and ketorolac tromethamine. Am J Hosp Pharm 1994 ; 51: 2963.
228	Revue	Mendenhall A, Hoyt DB. Incompatibility of ketorolac tromethamine with haloperidol lactate and triethylperazine maleate. Am J Hosp Pharm 1994 ; 51: 2964.
299	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
451	Revue	Das Gupta V, Maswoswe J, Bailey RE. Stability of ketorolac tromethamine in 5% dextrose injection and 0.9% sodium chloride injections. Int J Pharm Compound 1997 ; 1: 206-207.
469	Revue	Floy BJ, Royko CJ, Fleitman JS. Compatibility of ketorolac tromethamine injection with common infusion fluids and administration sets. Am J Hosp Pharm 1990 ; 47: 1097-1100.
476	Revue	Knapp AJ, Mauro VF, Alexander KS. Incompatibility of ketorolac tromethamine with selected postoperative drugs. Am J Hosp Pharm 1992 ; 49: 2960-2962.
1634	Revue	Shi A, Walker SE, Law S. Stability of ketorolac tromethamine in IV solutions and waste reduction. Can J Hosp Pharm 2000 ; 53: 263-269.
1712	Revue	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1721	Revue	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1800	Revue	Voytilla KL, Tyler LS, Rusho WJ. Visual compatibility of azithromycin with 24 commonly used drugs during simulated Y-site delivery. Am J Health-Syst Pharm 2002 ; 59: 853-855.
1803	Revue	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1859	Revue	Anacardio R, Perilli O, Pagnanelli F, Bartolini S, gentile MM, Mazzeo P, Carlucci G. Physicochemical compatibility between thiocolchicoside injections (Miotens®) and pharmaceutical products frequently used for combined therapy. Il Farmaco 2002 ; 57: 925-930.
1974	Revue	Chandler SW, Trissel LA, Weinstein SM Combined administration of opioids with selected drugs to manage pain and other cancer symptoms initial safety screening for compatibility. J Pain Symptom Manage 1996 ; 12, 3: 168-171.
2015	Revue	Hecq JD, Boitquin LP, Vanbeckbergen DF, Jamart J, Galanti LM. Effect of freezing, long term storage, and microwave thawing on the stability of ketorolac tromethamine. Ann Pharmacotherapy 2005 39: 1654-1658.
2124	Revue	Hecq JD, Boitquin L, Lebrun C, Vanbeckbergen D, Evrard JM, Jamart J, Galanti L. Freeze thaw treatment of ketorolac tromethamine in 5% dextrose infusion polyolein bags: effect of drug concentration and microwave power on the long-term stability at 4°C. EJHP Science 2006 ; 12, 4: 72-75.
2166	Revue	Nassr S, Dubuc MC, Lavoie P, Brazier JL. HPLC-DAD methods for studying the stability of solutions containing hydromorphone, ketorolac, haloperidol, midazolam, famotidine, metoclopramide, dimenhydrinate and scopolamine. J Liquid Chrom Rel Technol 2003 ; 26, 17: 2909-2929.

3159	Revue	Lin, T.-F., Lin, F.-S., Chou, W.-H., Yeh, Y.-C., Lin, C.-P., Fan, S.-Z., Sun, W.-Z. Compatibility and stability of binary mixtures of ketorolac tromethamine and tramadol hydrochloride injection concentrate and diluted infusion solution. Acta Anaesthesiol Taiwan 2010 ; 48, 3 : 117-121.
3169	Revue	Raffaelli W, Pari G, Visani L et al. Experimentation about precipitation of pharmacological association: morphine and ketorolac. Pain Clinic 1999 ; 11: 213-216.
3374	Revue	Smith R.P.R, Jones M. Precipitation in Manchester: ketorolac/cyclizine Anaesthesia 2001 ; 56: 494-495.
3470	Revue	Destro M, Ottolini L, Vicentini L, Boschetti S. Physical compatibility of binary and tertiary mixtures of morphine and methadone with other drugs for parenteral administration in palliative care. Support Care Cancer 2012 ; 20: 2501-2509.
3571	Revue	Anderson C, Boehme S, Ouellette J, Stidham C, MacKay M. Physical and Chemical Compatibility of Injectable Acetaminophen During Simulated Y-Site Administration. Hosp Pharm 2014 ; 49, 1: 42-47.
3593	Laboratoire	Ketorolac trometamol (Ketorolac®) - Summary of Product Characteristics Beacon Pharmaceuticals 2011
3601	Laboratoire	Cisatracurium Actavis - Résumé des Caractéristiques du Produit Actavis 2012
4433	Revue	Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485.
4435	Revue	Hanifah S, Nugroho B.H, Chabib L. Compatibility of acetaminophen with central nervous system medications during simulated Y-site injection. Anaesthesiol Intensive Ther 2020 ; 52, 1: 23-27.



Dictionnaire

 Antiinflammatoire	 Injectable
 Noms commerciaux	 Stabilité des solutions
 Contenant	 Molécule
 Concentration	 Température
 Conservation	 Durée de stabilité
 Biosimilaire	 Données conflictuelles
 Bibliographie	 Verre
 NaCl 0,9% ou glucose 5%	 Lumière
 Heure	 Polyvinyl chlorure
 Non précisée	 Jour
 Chlorure de sodium 0,9%	 A l'abri de la lumière
 Glucose 5%	RL Ringer lactate
 Polyéthylène	 Stabilité en mélange
 Solvant	 Molécule
 Aucun	 Polypropylène
 Seringue polypropylène	 Eau pour préparation injectable
 Compatibilités	 Précipitation immédiate
 Incompatible	 Compatible
 Incompatibilité non précisée	 Perte de turbidité
 Turbidité immédiate	 Solvant spécifique
 Précipitation en 1 heure	 Voie d'administration
 Intraveineuse	 Intramusculaire
 Sous cutanée	 Bibliographie
 Dictionnaire	